Literature DB >> 22714709

Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances.

Guo-shun Shu1, Fang Lv, Zhu-lin Yang, Xiong-ying Miao.   

Abstract

BACKGROUND: Gallbladder cancers have a very poor prognosis without specific molecular marker being identified. In this study we studied PUMA, c-Myb and p53 expression in benign and malignant lesions of gallbladder and analyzed their clinicopathological significance.
METHOD: Immunohistochemical staining of PUMA, c-Myb and p53 protein was performed in 108 gallbladder adenocarcinomas, 46 peritumoral tissues, 15 polyps, and 35 chronic cholecystitis.
RESULTS: We demonstrated that the percent of positive PUMA, c-Myb and p53 expression was significantly higher in gallbladder adenocarcinomas than in peritumoral tissues, polyps and chronic cholecystitis (p < 0.05 or 0.01). Benign gallbladder epithelium with positive PUMA, c-Myb or p53 expression showed moderately or severely atypical hyperplasia. The percent of positive PUMA, c-Myb and p53 expression was significantly higher in the cases having poorly differentiated adenocarcinoma with large tumor mass, lymph node metastasis and high invasiveness than cases with well-differentiated adenocarcinoma with small tumor mass and without metastasis and invasiveness (p < 0.05 or p < 0.01). The percent of positive PUMA, c-Myb and p53 expression was significantly higher in cases with radical resection than without resection (p < 0.05). Univariate Kaplan-Meier analysis showed that PUMA, c-Myb and p53 expression was associated with decreased overall survival (p < 0.05 or p < 0.01). Multivariate Cox regression analysis showed that PUMA, c-Myb or p53 expression was a poor-prognostic predictor in gallbladder adenocarcinoma.
CONCLUSION: PUMA, c-Myb and p53 expression closely relates to the carcinogenesis, fast-progression, easy-metastasis, high-invasion, and poor-prognosis in gallbladder adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22714709     DOI: 10.1007/s10147-012-0431-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  52 in total

1.  PUMA, a novel proapoptotic gene, is induced by p53.

Authors:  K Nakano; K H Vousden
Journal:  Mol Cell       Date:  2001-03       Impact factor: 17.970

2.  Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer.

Authors:  Rutger Middelburg; Richard R de Haas; Henk Dekker; Ron M Kerkhoven; Paula R Pohlmann; Adolfo Fuentes-Alburo; Alejandro Mohar; Herbert M Pinedo; Jan Lankelma
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

3.  NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model.

Authors:  Jean-Simon Diallo; Abdulhadi Aldejmah; Abdelali Filali Mouhim; Benjamin Péant; Mona Alam Fahmy; Ismaël Hervé Koumakpayi; Kanishka Sircar; Louis R Bégin; Anne-Marie Mes-Masson; Fred Saad
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

Review 4.  MYB function in normal and cancer cells.

Authors:  Robert G Ramsay; Thomas J Gonda
Journal:  Nat Rev Cancer       Date:  2008-07       Impact factor: 60.716

5.  [Histogenesis of carcinoma of gallbladder. Histological study of serial sections of 1000 cases of resected gallbladder].

Authors:  H Yamagiwa; H Tomiyama; H Yoshimura
Journal:  Rinsho Byori       Date:  1986-04

6.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

Authors:  E H Cheng; M C Wei; S Weiler; R A Flavell; T W Mak; T Lindsten; S J Korsmeyer
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

7.  Expression of Bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma.

Authors:  Cláudia Malheiros Coutinho-Camillo; Silvia Vanessa Lourenço; Ines Nobuko Nishimoto; Luiz Paulo Kowalski; Fernando Augusto Soares
Journal:  Histopathology       Date:  2010-08       Impact factor: 5.087

8.  Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas.

Authors:  Hee Jin Chang; Byong Chul Yoo; Sun Whe Kim; Byung Lan Lee; Woo Ho Kim
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

9.  The histogenesis of adenocarcinoma of the gallbladder.

Authors:  G P Dowling; J K Kelly
Journal:  Cancer       Date:  1986-10-15       Impact factor: 6.860

10.  Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma.

Authors:  Yuichi Sanada; Kazuhiro Yoshida; Masahiro Ohara; Yasuhiro Tsutani
Journal:  Pathol Oncol Res       Date:  2007-07-03       Impact factor: 3.201

View more
  5 in total

1.  Deregulation of MYC and TP53 through genetic and epigenetic alterations in gallbladder carcinomas.

Authors:  Geraldo Ishak; Mariana Ferreira Leal; Ney Pereira Carneiro Dos Santos; Samia Demachki; Caroline Aquino Moreira Nunes; Barbara do Nascimento Borges; Danielle Queiroz Calcagno; Marília Cardoso Smith; Paulo Pimentel Assumpção; Rommel Rodríguez Burbano
Journal:  Clin Exp Med       Date:  2014-09-09       Impact factor: 3.984

2.  Report of a case with gallbladder carcinoma: P53 expression of the peritumor epithelium might predict biliary tract recurrence.

Authors:  Atsushi Takano; Hiroshi Nakagomi; Kou Ikegame; Atsushi Yamamoto; Hideki Watanabe; Haruka Nakada; Masayuki Inoue; Hidemitsu Sugai; Michiya Yasutome; Kazushige Furuya; Masao Hada; Yoshiaki Miyasaka; Toshio Oyama; Masao Omata
Journal:  Int J Surg Case Rep       Date:  2016-10-18

3.  Evaluation of P53, E-cadherin, Cox-2, and EGFR protein immunoexpression on prognostic of resected gallbladder carcinoma.

Authors:  Sergio Renato Pais-Costa; José Francisco de Matos Farah; Ricardo Artigiani-Neto; Sandro José Martins; Alberto Goldenberg
Journal:  Arq Bras Cir Dig       Date:  2014 Apr-Jun

4.  MYB is a novel regulator of pancreatic tumour growth and metastasis.

Authors:  Sanjeev K Srivastava; Arun Bhardwaj; Sumit Arora; Seema Singh; Shafquat Azim; Nikhil Tyagi; James E Carter; Bin Wang; Ajay P Singh
Journal:  Br J Cancer       Date:  2015-12-10       Impact factor: 7.640

Review 5.  Overview of current targeted therapy in gallbladder cancer.

Authors:  Xiaoling Song; Yunping Hu; Yongsheng Li; Rong Shao; Fatao Liu; Yingbin Liu
Journal:  Signal Transduct Target Ther       Date:  2020-10-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.